Zhao YJ, et al. - In an all-comer percutaneous coronary intervention (PCI) registry, researchers looked at biodegradable polymer drug-eluting stents (BP-DES) vs second-generation durable polymer drug-eluting stents (DP-DES) with respect to clinical outcomes. Propensity score matching was performed to account for potential confounders and resulted in 497 patient pairs. At 1 year, the rates of target lesion failure (TLF) were comparable between BP-DES and DP-DES, with no significant differences in other clinical outcomes, including target vessel failure, stent thrombosis, in-stent restenosis, and cardiac death. Overall, one-year follow-up revealed no better efficacy and safety of BP-DES than DP-DES.